Working… Menu

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03984097
Recruitment Status : Active, not recruiting
First Posted : June 12, 2019
Last Update Posted : March 26, 2021
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 30, 2021
Estimated Study Completion Date : May 29, 2023